Bonesupport Holding AB
STO:BONEX
Bonesupport Holding AB
Revenue
Bonesupport Holding AB
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bonesupport Holding AB
STO:BONEX
|
Revenue
kr997.9m
|
CAGR 3-Years
62%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Revenue
kr1.4B
|
CAGR 3-Years
22%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Revenue
kr3.6B
|
CAGR 3-Years
21%
|
CAGR 5-Years
19%
|
CAGR 10-Years
21%
|
|
|
Probi AB
STO:PROB
|
Revenue
kr630.4m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
0%
|
CAGR 10-Years
18%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Revenue
kr26B
|
CAGR 3-Years
19%
|
CAGR 5-Years
13%
|
CAGR 10-Years
26%
|
|
|
BioArctic AB
STO:BIOA B
|
Revenue
kr257.4m
|
CAGR 3-Years
123%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
Bonesupport Holding AB
Glance View
Bonesupport Holding AB, a Swedish company, has carved a niche for itself in the intricate world of orthopedic treatments and regenerative medicine. Founded in 1999, the company's journey is rooted in innovation and development of injectable bio-ceramic bone graft substitutes, primarily aimed at addressing bone voids and other skeletal maladies. The cornerstone of their business is the proprietary CERAMENT platform, which combines biocompatible, synthetic materials with a unique ability to promote bone healing and integration. By offering solutions that are resorbable and can enhance the regrowth of natural bone, Bonesupport targets clinicians and professionals in orthopedics, trauma, and spine surgery, offering them alternatives to traditional bone grafting methods. The company's products, including CERAMENT BONE VOID FILLER, CERAMENT G, and CERAMENT V, differentiate themselves by also being antibiotic-eluting—allowing for the simultaneous treatment of bone diseases and infection mitigation. Bonesupport's revenue models revolve around both direct sales and leveraging distribution partnerships in key markets, including Europe, the United States, and emerging regions. The company channels substantial investments into research and development, seeking to broaden the clinical applications of their technologies thus driving adoption in the market. They benefit from a growing interest in minimally invasive treatments among healthcare providers, who aim to enhance patient outcomes while also controlling costs. By continuing to expand its product portfolio and advancing clinical evidence, Bonesupport maintains a competitive edge in skeletal health, translating innovation and efficacy into profitability and market growth. This strategic pursuit of advanced bone treatment technologies underscores their role in transforming standard medical practices, ensuring they remain at the forefront of bone health solutions.
See Also
What is Bonesupport Holding AB's Revenue?
Revenue
997.9m
SEK
Based on the financial report for Mar 31, 2025, Bonesupport Holding AB's Revenue amounts to 997.9m SEK.
What is Bonesupport Holding AB's Revenue growth rate?
Revenue CAGR 5Y
43%
Over the last year, the Revenue growth was 52%. The average annual Revenue growth rates for Bonesupport Holding AB have been 62% over the past three years , 43% over the past five years .
You don't have any saved screeners yet